Neuropathic Pain Management -Global Market Status and Trend Report 2013-2023

Table of Contents

Chapter 1 Overview of Neuropathic Pain Management

• 1.1 Definition of Neuropathic Pain Management in This Report
• 1.2 Commercial Types of Neuropathic Pain Management
  • 1.2.1 Tricyclic Antidepressant
  • 1.2.2 Anticonvulsant
  • 1.2.3 Opioid
  • 1.2.4 Steroid Drug
  • 1.2.5 Local Anesthesia
  • 1.2.6 Other
• 1.3 Downstream Application of Neuropathic Pain Management
  • 1.3.1 Retail Pharmacy
  • 1.3.2 Hospital Pharmacy
  • 1.3.3 Other
• 1.4 Development History of Neuropathic Pain Management
• 1.5 Market Status and Trend of Neuropathic Pain Management 2013-2023
  • 1.5.1 Global Neuropathic Pain Management Market Status and Trend 2013-2023
  • 1.5.2 Regional Neuropathic Pain Management Market Status and Trend 2013-2023

Chapter 2 Global Market Status and Forecast by Regions

• 2.1 Market Development of Neuropathic Pain Management 2013-2017
• 2.2 Production Market of Neuropathic Pain Management by Regions
  • 2.2.1 Production Volume of Neuropathic Pain Management by Regions
  • 2.2.2 Production Value of Neuropathic Pain Management by Regions
• 2.3 Demand Market of Neuropathic Pain Management by Regions
• 2.4 Production and Demand Status of Neuropathic Pain Management by Regions
  • 2.4.1 Production and Demand Status of Neuropathic Pain Management by Regions 2013-2017
  • 2.4.2 Import and Export Status of Neuropathic Pain Management by Regions 2013-2017

Chapter 3 Global Market Status and Forecast by Types

• 3.1 Production Volume of Neuropathic Pain Management by Types
• 3.2 Production Value of Neuropathic Pain Management by Types
• 3.3 Market Forecast of Neuropathic Pain Management by Types

Chapter 4 Global Market Status and Forecast by Downstream Industry

• 4.1 Demand Volume of Neuropathic Pain Management by Downstream Industry
• 4.2 Market Forecast of Neuropathic Pain Management by Downstream Industry

Chapter 5 Market Driving Factor Analysis of Neuropathic Pain Management

• 5.1 Global Economy Situation and Trend Overview
• 5.2 Neuropathic Pain Management Downstream Industry Situation and Trend Overview

Chapter 6 Neuropathic Pain Management Market Competition Status by Major Manufacturers

• 6.1 Production Volume of Neuropathic Pain Management by Major Manufacturers
• 6.2 Production Value of Neuropathic Pain Management by Major Manufacturers
• 6.3 Basic Information of Neuropathic Pain Management by Major Manufacturers
  • 6.3.1 Headquarters Location and Established Time of Neuropathic Pain Management Major Manufacturer
  • 6.3.2 Employees and Revenue Level of Neuropathic Pain Management Major Manufacturer
• 6.4 Market Competition News and Trend
  • 6.4.1 Merger, Consolidation or Acquisition News
  • 6.4.2 Investment or Disinvestment News
  • 6.4.3 New Product Development and Launch

Chapter 7 Neuropathic Pain Management Major Manufacturers Introduction and Market Data

• 7.1 Biogen Idec
  • 7.1.1 Company profile
  • 7.1.2 Representative Neuropathic Pain Management Product
  • 7.1.3 Neuropathic Pain Management Sales, Revenue, Price and Gross Margin of Biogen Idec
• 7.2 Baxter Healthcare Corporation
  • 7.2.1 Company profile
  • 7.2.2 Representative Neuropathic Pain Management Product
  • 7.2.3 Neuropathic Pain Management Sales, Revenue, Price and Gross Margin of Baxter Healthcare Corporation
• 7.3 GlaxoSmithKline
  • 7.3.1 Company profile
  • 7.3.2 Representative Neuropathic Pain Management Product
  • 7.3.3 Neuropathic Pain Management Sales, Revenue, Price and Gross Margin of GlaxoSmithKline
• 7.4 Johnson & Johnson Services
  • 7.4.1 Company profile
  • 7.4.2 Representative Neuropathic Pain Management Product
  • 7.4.3 Neuropathic Pain Management Sales, Revenue, Price and Gross Margin of Johnson & Johnson Services
• 7.5 Pfizer
  • 7.5.1 Company profile
  • 7.5.2 Representative Neuropathic Pain Management Product
  • 7.5.3 Neuropathic Pain Management Sales, Revenue, Price and Gross Margin of Pfizer
• 7.6 Sanofi
  • 7.6.1 Company profile
  • 7.6.2 Representative Neuropathic Pain Management Product
  • 7.6.3 Neuropathic Pain Management Sales, Revenue, Price and Gross Margin of Sanofi
• 7.7 Bristol-Myers Squibb
  • 7.7.1 Company profile
  • 7.7.2 Representative Neuropathic Pain Management Product
  • 7.7.3 Neuropathic Pain Management Sales, Revenue, Price and Gross Margin of Bristol-Myers Squibb
• 7.8 Eli Lilly and Company
  • 7.8.1 Company profile
  • 7.8.2 Representative Neuropathic Pain Management Product
  • 7.8.3 Neuropathic Pain Management Sales, Revenue, Price and Gross Margin of Eli Lilly and Company
• 7.9 Depomed
  • 7.9.1 Company profile
  • 7.9.2 Representative Neuropathic Pain Management Product
  • 7.9.3 Neuropathic Pain Management Sales, Revenue, Price and Gross Margin of Depomed

Chapter 8 Upstream and Downstream Market Analysis of Neuropathic Pain Management

• 8.1 Industry Chain of Neuropathic Pain Management
• 8.2 Upstream Market and Representative Companies Analysis
• 8.3 Downstream Market and Representative Companies Analysis

Chapter 9 Cost and Gross Margin Analysis of Neuropathic Pain Management

• 9.1 Cost Structure Analysis of Neuropathic Pain Management
• 9.2 Raw Materials Cost Analysis of Neuropathic Pain Management
• 9.3 Labor Cost Analysis of Neuropathic Pain Management
• 9.4 Manufacturing Expenses Analysis of Neuropathic Pain Management

Chapter 10 Marketing Status Analysis of Neuropathic Pain Management

• 10.1 Marketing Channel
  • 10.1.1 Direct Marketing
  • 10.1.2 Indirect Marketing
  • 10.1.3 Marketing Channel Development Trend
• 10.2 Market Positioning
  • 10.2.1 Pricing Strategy
  • 10.2.2 Brand Strategy
  • 10.2.3 Target Client
• 10.3 Distributors/Traders List

Chapter 11 Report Conclusion

Chapter 12 Research Methodology and Reference

• 12.1 Methodology/Research Approach
  • 12.1.1 Research Programs/Design
  • 12.1.2 Market Size Estimation
  • 12.1.3 Market Breakdown and Data Triangulation
• 12.2 Data Source
  • 12.2.1 Secondary Sources
  • 12.2.2 Primary Sources